Claims for Patent: 10,253,108

Summary for Patent: 10,253,108

Title:	Mutated antibody of fully humanized HER2 antibody, and encoding gene and use thereof
Abstract:	The present invention provides a mutated antibody of the fully humanized HER2 antibody GB235-019, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the mutated antibody are respectively SEQ ID NO: 10, SEQ ID NO: 2; SEQ ID NO: 11, SEQ ID NO: 2; or SEQ ID NO: 12, SEQ ID NO: 2. The mutated antibody has the ability to specifically bind to human HER2 antigen, similar to the GB235-019 antibody. They can also be used in combination with additional HER2 positive tumor therapeutic agents for treating HER2 positive tumor, weakly positive tumor or negative tumor.
Inventor(s):	Zhou; Qing (Shanghai, CN), Shu; Mengjun (Shanghai, CN), He; Zhuzi (Shanghai, CN), Lin; Jun (Shanghai, CN)
Assignee:	Genor Biopharma Co., Ltd. (Shanghai, CN)
Application Number:	15/304,199
Patent Claims:	1. A mutated fully human anti-HER2 antibody, comprising the amino acid sequence of SEQ ID NO:10 and SEQ ID NO:2; SEQ ID NO:11 and SEQ ID NO:2; or SEQ ID NO:12 and SEQ ID NO:2 for the heavy chain variable region and the light chain variable region of the antibody, respectively. 2. The mutated fully human anti-HER2 antibody according to claim 1, which is in the form of Fab, Fab', F(ab').sub.2, or scFv. 3. The mutated fully human anti-HER2 antibody according to claim 1, further comprising the heavy chain constant region and the light chain constant region of human IgG. 4. The mutated fully human anti-HER2 antibody according to claim 3, wherein the human IgG is IgG1. 5. The mutated fully human anti-HER2 antibody according to claim 3, wherein the amino acid sequence of the human IgG heavy chain constant region is SEQ ID NO:5, and the amino acid sequence of the human IgG light chain constant region is SEQ ID NO:6. 6. A pharmaceutical composition comprising the mutated fully human anti-HER2 antibody according to claim 1 and a pharmaceutically acceptable carrier. 7. A combined medicament comprising the mutated fully human anti-HER2 antibody of claim 1 and additional HER2 positive tumor therapeutic agent(s). 8. The combined medicament according to claim 7, wherein said additional HER2 positive tumor therapeutic agent(s) is herceptin or pertuzumab. 9. A kit for detecting human HER2 comprising the mutated fully human anti-HER2 antibody according to claim 1. 10. A method for treating a HER2 positive tumor in a subject, comprising administering to the subject the mutated fully human anti-HER2 antibody of claim 1. 11. The method according to claim 10, wherein the subject is a human having a HER2 positive tumor. 12. The method according to claim 10, wherein said HER2 positive tumor is selected from HER2 positive breast cancer, gastric cancer, lung cancer, non-small cell lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovary cancer, rectal cancer, anal cancer, colon cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue cancer, urethra cancer, penis cancer, prostate cancer, bladder cancer, kidney cancer, kidney cell cancer, renal pelvis cancer, mesothelioma, liver cell cancer, gallbladder cancer, chronic or acute leukemia, lymphatic cell lymphoma, central nerve system cancer, spinal tumor, neuroglioma of brain stem, glioblastoma multiforme, astrocytoma, neurilemmoma, ependymoma, medulloblastoma, meningioma, squamous cell carcinoma and pituitary adenoma.

Details for Patent 10,253,108

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998		2035-12-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017		2035-12-08
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	June 08, 2012		2035-12-08
Merck Sharp & Dohme Llc	ZINPLAVA	bezlotoxumab	Injection	761046	October 21, 2016		2035-12-08

International Patent Family for US Patent 10,253,108

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016119523
United States of America	2017037146
Russian Federation	2639531
South Korea	20160145185